CAAS Capital Management’s Exagen XGN Stock Holding History

CAAS Capital Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-24,349	Closed	-$426K	–	1318
2021 Q1	$426K	Buy	+24,349	New	+$434K	﹤0.01%	961

Other funds holding XGN

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

CAAS Capital Management's XGN Position: Q2 2021 in Review

CAAS Capital Management sold out of Exagen (XGN) in Q2 2021, closing a stake of 24,349 shares — an estimated $426K sold.

CAAS Capital Management first reported a position in XGN in Q1 2021 and held it in 1 quarter. The position peaked at $426K in Q1 2021. 54 funds tracked by Wall St. Rank hold XGN as of Q2 2021.

CAAS Capital Management reported no remaining Exagen position as of Q2 2021 after selling out during the quarter.
CAAS Capital Management sold 24,349 Exagen shares in Q2 2021, an estimated $426K.
CAAS Capital Management first reported a position in Exagen in Q1 2021 and held it in 1 quarter.
CAAS Capital Management's Exagen position peaked at $426K in Q1 2021.
54 funds tracked by Wall St. Rank held Exagen as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.